This study is a prospective, multi-cohort, multi-center clinical trial targeting patients with intermediate-to-high-risk rhabdomyosarcoma who have not previously received systemic anti-tumor treatment. It aims to evaluate the efficacy and safety of all-trans retinoic acid combined with VAC chemotherapy.
Age ≥ 14 years old and ≤ 60 years old;
Histologically confirmed medium to high risk rhabdomyosarcoma (excluding pleomorphic rhabdomyosarcoma);
The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0-1;
Have not received any anti-tumor drug treatment in the past;
Previously received anti-tumor treatment other than surgery and radiation therapy for any malignant tumor;
Subjects who cannot accept or tolerate this chemotherapy regimen for various reasons;
Biopsy confirmed a patient with bone marrow infiltration;
Patients who have undergone major surgical procedures unrelated to medium to high risk rhabdomyosarcoma within the 4 weeks prior to enrollment, or who have not fully recovered from such surgical procedures;